🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Paul Tudor Jones’s VOR Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+167,673 Shares
Current Position
167,673 Shares
$2.19 M Value

Paul Tudor Jones's VOR Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 167,673 shares of Vor Biopharma Inc. (VOR) worth $2.19 M, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Paul Tudor Jones has initiated a new position in VOR, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Vor Biopharma (VOR) Holding Value Over Time

Track share changes against reported price movement

Quarterly Vor Biopharma (VOR) Trades by Paul Tudor Jones

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +167,673 New Buy 167,673 $13.08

Paul Tudor Jones's Vor Biopharma Investment FAQs

Paul Tudor Jones first purchased Vor Biopharma Inc. (VOR) in Q4 2025, acquiring 167,673 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Vor Biopharma Inc. (VOR) for 1 quarters since Q4 2025.

Paul Tudor Jones's largest addition to Vor Biopharma Inc. (VOR) was in Q4 2025, adding 167,673 shares worth $2.19 M.

According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 167,673 shares of Vor Biopharma Inc. (VOR), valued at approximately $2.19 M.

As of the Q4 2025 filing, Vor Biopharma Inc. (VOR) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.

Paul Tudor Jones's peak holding in Vor Biopharma Inc. (VOR) was 167,673 shares, as reported at the end of Q4 2025.